> Back to seminars list

Seminar

Wednesday, March 21st, 2018
From 14h To 15h30
Centre de Recherche - Paris - Amphith√©√Ętre Antoine Lacassagne

#1: Computational ImmunoEngineering & the Synthetic Biology Revolution: lessons in T-cell receptor engineering, antibody engineering, (....) - #2: Applied computational immunology: validation of a universal vaccine techn. in influenza & pigs

Abstract #1: Jacob Glanville
Adaptive immunity is predicated on combinatorial complexity. This complexity enables the body to continuously defend itself against a universe of ever-evolving pathogens, but has also frustrated efforts to analyze and characterize adaptive immune function. In the last decade, advances in high-throughput sequencing and high-throughput synthesis have dramatically altered our ability to interrogate and alter adaptive immune repertoires at scale. Here we present a history of the emerging field of computational immunology and immunoEngineering through a series of case studies in B-cell and T-cell repertoire sequencing, single-cell sequencing technologies, antibody repertoire engineering, T-cell specificity engineering, and recent advances in computational methods for rapidly identifying the specificity of TCRs and BCRs from primary sequence using the GLIPH algorithm.

Abstract #2: Sarah Ives
In the last century, vaccines have significantly reduced and even eradicated many historically pervasive pathogens. However, rapidly mutating or naturally polymorphic pathogens of HIV, influenza, Chagas disease, sleeping sickness, Dengue and Zika continue to pose challenges to vaccine science. Here, we demonstrate a universal influenza vaccine Centivax using a computationally guided epitope focusing technology. In two repeat studies in sus scrofa (pig), the epitope focusing vaccine induced antibodies against 39 viral strains of influenza spanning the last century, including all pandemic events (1918 H1N1 Spanish flu, 1957 H2N2 Asian flu, 1968 H3N2 Hong Kong flu, 1977 H1N1 Russian flu, 2002 H3N2 Fujian flu, and 2009 H1N1 Swine flu). In a pre-2009 Centivax design, the vaccine further elicited broad neutralizing immunity against future viral strains. Observation of an inverse-dose response, single antigen tests, and 159 monoclonal pig antibodies recovered from immunized animals further clarify the mechanism of epitope focusing by Centivax. We explore immunological features of this broad response and discuss plans to apply the technology to other rapidly mutating pathogen systems.

Speaker(s)

Jacob GLANVILLE
Co-founder & CSO, Distributed Bio, Distributed Bio
Sarah IVES
Scientist, Distributed Bio

Invited by

Olivier LANTZ

Institut Curie

Contact

Olivier LANTZ

Institut Curie

Sylvia TRIVAL

To sum up

Jacob Glanville is an Entrepreneur and Computational Immuno-Engineer. He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing (PNAS 2009), repertoire decoding algorithms (Nature 2017), single-cell TCR receptor & phenotype sequencing (Nature Biotech, 2014), deconstructing genetic variation in the adaptive immune system (Nature Communications 2015, Nature Reports 2016, PNAS 2011, TI 2017), and computationally guided antibody library engineering (JMB 2011, JMB 2013, COSB 2015).

He is a Stanford University Scientific Advisory Committee member for the Sean Parker Center for Allergy and Asthma Research, a Scientific Advisory Board member for the University of San Francisco's Biotechnology program, a Gates Foundation/Stanford University Computational and Systems Immunology Grant Recipient while a PhD Candidate with Mark Davis at Stanford, a Recipient of Pfizer Achievement award 2010 while Principal Scientist at Pfizer, and has been a course-founding instructor and guest lecturer for multiple graduate-level applied computational and systems immunology courses at Stanford and USF.

As Co-Founder and Chief Science Officer of Distributed Bio, he and his teams apply computationally-guided immunoengineering methods to enable a new generation of monoclonal antibody discovery and universal vaccine design. In addition to counting over 40 pharmaceutical companies and biotechnology startups as his Distributed Bio clients, he enjoys collaborating with multiple partners including Twist Bioscience, AbCheck, and Isogenica to generate exciting new technologies in biomedicine.

---------

Sarah Ives received a BSc degree in Molecular Biology from University of Wisconsin, Madison, where she contributed to published research in developmental biology in the Bashirullah lab in the School of Pharmacy. She then received a PSM degree from the University of San Francisco Biotechnology Masters Program, where she contributed to published research in virology while interning in the Delwart lab at the Blood Systems Research Institute. After graduation she became an Associate Scientist and Project Manager at LakePharma, where she managed client projects, performed sales outreach, developed custom bioanalytics immuno-assays, and organized the Bay Area Antibody Engineering Symposium in her role of Master of Ceremonies. In 2015 she joined Distributed Bio as employee #6 to lead the universal vaccine laboratory and vivarium operations in California and Guatemala as a Senior Scientist. In addition to the vaccine research, she supports monoclonal therapeutic discovery efforts with bioanalytics, bioassay development, and phage library development. In her spare time, she performed research community organization, acting as Associate Producer for the NPR radio show “Biotech Nation” hosted by Dr. Moira Gunn at BIO International Convention, in 2015 and 2016.